Shared neoantigens for cancer immunotherapy

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Neoantigens are tumor-specific antigens derived from genetic alterations in cancer cells.
• These alterations include point mutations, gene rearrangements, and viral integrations, leading to unique epitopes.
• Neoantigens are absent in healthy tissues, reducing the risk of autoimmunity and enabling immune responses.

Purpose of the Study:

• To review the two categories of neoantigens: private and shared.
• To discuss the application of neoantigens in immuno-oncotherapy through pre-clinical and clinical studies.
• To explore the potential of shared neoantigens for developing broad-spectrum therapeutic vaccines.

Main Methods:

• Overview of existing literature on neoantigen discovery and characterization.
• Analysis of pre-clinical and clinical studies utilizing neoantigens in cancer treatment.
• Categorization of neoantigens into private and shared types.

Main Results:

• Neoantigens arise from various genetic instabilities, with a small percentage yielding T cell-detectable neoepitopes.
• Private neoantigens are unique to individual tumors, while shared neoantigens are found across multiple tumors.
• Shared neoantigens, when combined with effective vaccine platforms, can lead to 'off-the-shelf' therapeutic vaccines.

Conclusions:

• Neoantigens represent a valuable target class for cancer immuno-oncotherapy.
• Shared neoantigens hold significant promise for developing non-personalized, broadly applicable cancer vaccines.
• Further research into shared neoantigens can advance the development of effective immunotherapy strategies.